ZA201005741B - Therapeutic peptidomimetic macrocycles - Google Patents

Therapeutic peptidomimetic macrocycles

Info

Publication number
ZA201005741B
ZA201005741B ZA2010/05741A ZA201005741A ZA201005741B ZA 201005741 B ZA201005741 B ZA 201005741B ZA 2010/05741 A ZA2010/05741 A ZA 2010/05741A ZA 201005741 A ZA201005741 A ZA 201005741A ZA 201005741 B ZA201005741 B ZA 201005741B
Authority
ZA
South Africa
Prior art keywords
peptidomimetic macrocycles
therapeutic
therapeutic peptidomimetic
macrocycles
peptidomimetic
Prior art date
Application number
ZA2010/05741A
Other languages
English (en)
Inventor
Noriyuki Kawahata
Tomi K Sawyer
Rosana Kapeller-Libermann
David Allen Annis
Huw M Nash
Jiawen Han
Original Assignee
Aileron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc
Publication of ZA201005741B publication Critical patent/ZA201005741B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2010/05741A 2008-02-08 2010-08-11 Therapeutic peptidomimetic macrocycles ZA201005741B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732608P 2008-02-08 2008-02-08
US12038008P 2008-12-05 2008-12-05
PCT/US2009/000837 WO2009099677A2 (en) 2008-02-08 2009-02-09 Therapeutic peptidomimetic macrocycles

Publications (1)

Publication Number Publication Date
ZA201005741B true ZA201005741B (en) 2018-11-28

Family

ID=40952614

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/05741A ZA201005741B (en) 2008-02-08 2010-08-11 Therapeutic peptidomimetic macrocycles

Country Status (12)

Country Link
US (4) US20090275519A1 (enExample)
EP (2) EP2242503A4 (enExample)
JP (2) JP2011511076A (enExample)
KR (1) KR20100126361A (enExample)
CN (2) CN101980718A (enExample)
BR (1) BRPI0907754A2 (enExample)
CA (1) CA2714251C (enExample)
DE (1) DE112009000300T5 (enExample)
GB (1) GB2471588A (enExample)
IL (2) IL207421A0 (enExample)
WO (1) WO2009099677A2 (enExample)
ZA (1) ZA201005741B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2091552A4 (en) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc STABILIZED MAML-PEPTIDES AND ITS USES
EP3170835A1 (en) * 2006-12-14 2017-05-24 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
CN101980718A (zh) 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
BRPI0918838A2 (pt) * 2008-09-22 2015-12-08 Aileron Therapeutics Inc processos para preparação de composições de polipeptídeos purificados
AU2009294877C1 (en) * 2008-09-22 2015-05-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2009316288B2 (en) 2008-11-24 2016-05-19 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) * 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
CN102958364A (zh) 2010-05-28 2013-03-06 德克萨斯大学系统董事会 低聚苯甲酰胺化合物及其用途
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
WO2012051405A1 (en) 2010-10-13 2012-04-19 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
WO2012065181A2 (en) 2010-11-12 2012-05-18 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2013116829A1 (en) * 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR20150034209A (ko) * 2012-06-26 2015-04-02 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN106604928A (zh) * 2014-04-02 2017-04-26 罗契斯特大学 用于α‑螺旋拟态的大环肽模拟物
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
JP2018511594A (ja) * 2015-03-18 2018-04-26 マサチューセッツ インスティテュート オブ テクノロジー 選択的ｍｃｌ−１結合ペプチド
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MX380314B (es) 2015-09-22 2025-03-12 Univ California Citotoxinas modificadas y su uso terapeutico.
HRP20201273T1 (hr) 2015-10-27 2020-11-13 F. Hoffmann - La Roche Ag Peptidni makrocikli protiv bakterije acinetobacter baumannii
US20190077840A1 (en) * 2015-10-30 2019-03-14 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11524979B2 (en) 2017-06-15 2022-12-13 University Of Washington Macrocyclic polypeptides
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
CA3132993A1 (en) * 2019-03-15 2020-09-24 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
IL309067A (en) 2021-06-09 2024-02-01 Scripps Research Inst Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2023069332A1 (en) * 2021-10-22 2023-04-27 Merck Sharp & Dohme Llc Cell permeable macrocyclic peptides useful for eif4e cap-binding site inhibition

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753819A (en) * 1903-04-08 1904-03-01 George Jones Atkins Electrode.
US5712418A (en) * 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
EP0488258B1 (en) 1990-11-27 1996-04-17 Fuji Photo Film Co., Ltd. Propenamide derivatives, polymers, copolymers and use thereof
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
JP3067031B2 (ja) * 1992-04-03 2000-07-17 カリフォルニア インスティチュート オブ テクノロジー オレフィンメタセシス重合方法
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US6407059B1 (en) * 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US5663316A (en) * 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) * 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
CA2304124A1 (en) * 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
CN1163504C (zh) 1998-04-15 2004-08-25 阿温蒂斯药物公司 制备与树脂结合的环状肽的方法
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
PT1165613E (pt) * 1999-03-29 2008-07-29 Procter & Gamble Ligantes do receptor de melanocortina
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2000059526A1 (en) * 1999-04-07 2000-10-12 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US6703382B2 (en) * 2000-08-16 2004-03-09 Georgetown University Medical Center Small molecule inhibitors targeted at Bcl-2
JP2004530422A (ja) 2000-12-19 2004-10-07 ザ ジョンズ ホプキンス ユニバーシティ 急速なアポトーシスを誘導するｊｆｙ１蛋白質
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2003057158A2 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
AU2003267124A1 (en) * 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1581904A2 (en) * 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
US20070207947A1 (en) 2003-10-16 2007-09-06 Aplagen Gmbh Stabilized Peptides
EP1680443B9 (en) * 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) * 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
US7501397B2 (en) 2004-06-04 2009-03-10 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
EP1768966B1 (en) * 2004-06-17 2012-03-07 Infinity Discovery, Inc. Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP3170835A1 (en) * 2006-12-14 2017-05-24 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) * 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
CA2682174C (en) * 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
ES2637687T3 (es) * 2007-05-02 2017-10-16 Dana-Farber Cancer Institute, Inc. Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
CA2700925C (en) * 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
KR101108450B1 (ko) * 2007-11-20 2012-02-20 아사히 가세이 겐자이 가부시키가이샤 열경화성 수지 발포판의 제조 방법
CN101980718A (zh) 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
AU2009294877C1 (en) 2008-09-22 2015-05-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2009316288B2 (en) 2008-11-24 2016-05-19 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
US20110223149A1 (en) * 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Also Published As

Publication number Publication date
EP2242503A4 (en) 2012-04-25
CN101980718A (zh) 2011-02-23
US8808694B2 (en) 2014-08-19
JP2015078208A (ja) 2015-04-23
EP2926827A3 (en) 2015-11-04
JP2011511076A (ja) 2011-04-07
US20150038430A1 (en) 2015-02-05
US20120149648A1 (en) 2012-06-14
IL243240A (en) 2016-11-30
WO2009099677A3 (en) 2009-12-17
AU2009210682A1 (en) 2009-08-13
DE112009000300T5 (de) 2011-01-20
CA2714251A1 (en) 2009-08-13
BRPI0907754A2 (pt) 2015-07-21
GB2471588A (en) 2011-01-05
US20090275519A1 (en) 2009-11-05
GB201014734D0 (en) 2010-10-20
KR20100126361A (ko) 2010-12-01
EP2926827A2 (en) 2015-10-07
CN104474529A (zh) 2015-04-01
IL207421A0 (en) 2010-12-30
WO2009099677A2 (en) 2009-08-13
CA2714251C (en) 2017-08-15
US20190071469A1 (en) 2019-03-07
EP2242503A2 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
IL243240A (en) Therapeutic peptidomimetic macrocycles
IL211836A0 (en) Peptidomimetic macrocycles
IL219178A0 (en) Improved peptidomimetic macrocycles
IL212748A0 (en) Peptidomimetic macrocycles with improved properties
PL2603600T3 (pl) Makrocykle peptidomometyczne
GB0811304D0 (en) Therapeutic agents
IL206654A0 (en) Combination therapy
GB0908957D0 (en) Therapeutic agents
BRPI0918833A2 (pt) macrociclos peptidomiméticos
GB0819593D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0801080D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
GB0803054D0 (en) Medicament
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0803948D0 (en) Combination therapy
EP2454276A4 (en) THERAPEUTIC AGENTS
GB0811715D0 (en) Therapeutic agents
HK1145988A (en) Therapeutic peptidomimetic macrocycles
GB0814895D0 (en) An improved hydrotherapy unit
GB0910493D0 (en) Therapeutic agents
HK1160145A (en) Peptidomimetic macrocycles
HK1160144A (en) Peptidomimetic macrocycles